Tagged Articles

Tysbri 2 articles

Rheumatoid Arthritis drug linked to serious neurological disorder

The Food and Drug Administration (FDA) has received a third case of a serious and often fatal neurological disorder known as progressive multifocal leukoencephalopathy (PML) in a patient with rheumatoid arthritis (RA) treated with the drug Rituxan (rituximab). The report has led the agency to inform rheumatological health care professionals that patients with RA who have received Rituxan are at an increased risk of PML. Physicians should consider the risks in any patient treated with Rituxan who presents new onset neurological manifestations. The FDA advises consultation with a neurologist, brain MRI, and lumbar puncture should be considered as clinically indicated. ... Read More

Serious neurological disorder linked to MS, Crohn’s drug

A medication used to treat multiple sclerosis (MS) and Crohn’s disease has been linked to a serious and usually fatal neurological disorder, according to an alert issued to neurological health care professionals and their patients by the Food and Drug Administration (FDA). Natalizumab, marketed as Tysbri, was approved by the FDA in 2004 to treat relapsing forms of MS. In 2008, the FDA approved the drug’s use for moderately to severely active Crohn’s disease. From July 2006, when Tysabri marketing resumed, to September 8, 2009, there were 13 reported cases of Tysabri-related progressive multifocal leukoencephalopathy (PML) confirmed worldwide in patients ... Read More